BR112013025005A2 - composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico - Google Patents

composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico

Info

Publication number
BR112013025005A2
BR112013025005A2 BR112013025005A BR112013025005A BR112013025005A2 BR 112013025005 A2 BR112013025005 A2 BR 112013025005A2 BR 112013025005 A BR112013025005 A BR 112013025005A BR 112013025005 A BR112013025005 A BR 112013025005A BR 112013025005 A2 BR112013025005 A2 BR 112013025005A2
Authority
BR
Brazil
Prior art keywords
boronic acid
pharmaceutical composition
block copolymer
acid compound
composition containing
Prior art date
Application number
BR112013025005A
Other languages
English (en)
Inventor
Hiroyuki Saito
Katsutoshi Kobayashi
Mitsunori Harada
Ryosuke Tanaka
Yasuki Kato
Original Assignee
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocarrier Co Ltd filed Critical Nanocarrier Co Ltd
Publication of BR112013025005A2 publication Critical patent/BR112013025005A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico a presente invenção provê uma composição farmacêutica. a composição farmacêutica inclui um copolímero por blocos incluindo: um segmento hidrofílico; um segmento hidrofóbico; e um composto de ácido borônico ligado a uma cadeia lateral do segmento hidrofóbico via uma porção de ligador incluindo uma estrutura heterocíclica, em que: um esqueleto ciclico da estrutura heterocíclica tem um átomo de boro derivado do composto de ácido borônico, átomos x' s ligados ao átomo de boro e cada um selecionado dentre um átomo de oxigênio e um átomo de nitrogênio, e átomos de carbono ligados aos átomos x' s; e o copolímero por blocos ainda compreende um grupo orgânico ligado aos átomos de carbono, o grupo orgânico contendo um grupo aromático ou grupo alquila cíclico como uma estrutura para a proteção de uma ligação de éster de ácido borônico e/ou uma ligação de amida de boro que resultam de ligação entre o átomo de boro e os átomos x' s.
BR112013025005A 2011-03-31 2012-04-02 composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico BR112013025005A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011080509 2011-03-31
PCT/JP2012/058831 WO2012133884A1 (ja) 2011-03-31 2012-04-02 ボロン酸化合物を含有したブロック共重合体を含む医薬組成物

Publications (1)

Publication Number Publication Date
BR112013025005A2 true BR112013025005A2 (pt) 2017-01-17

Family

ID=46931571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025005A BR112013025005A2 (pt) 2011-03-31 2012-04-02 composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico

Country Status (12)

Country Link
US (1) US9561284B2 (pt)
EP (1) EP2692777B1 (pt)
JP (1) JP5086497B1 (pt)
KR (1) KR101869125B1 (pt)
CN (1) CN103502319B (pt)
AU (1) AU2012233171B2 (pt)
BR (1) BR112013025005A2 (pt)
CA (1) CA2828700A1 (pt)
MX (1) MX348798B (pt)
RU (1) RU2569847C2 (pt)
TW (1) TWI533885B (pt)
WO (1) WO2012133884A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012233171B2 (en) 2011-03-31 2015-08-20 Nanocarrier Co., Ltd. Pharmaceutical composition containing block copolymer comprising boronic acid compound
RU2014124333A (ru) 2011-11-17 2015-12-27 Дзе Юниверсити Оф Токио Блок-сополимер, имеющий введенную в него группу фенилбороновой кислоты, и его применение
US20160129117A1 (en) * 2013-07-03 2016-05-12 Nippon Kayaku Kabushiki Kaisha Novel Boronic Acid Compound Preparation
JP6566936B2 (ja) 2014-05-08 2019-08-28 国立大学法人 東京大学 医薬組成物
EP3270891A1 (en) * 2015-03-17 2018-01-24 Leon-Nanodrugs GmbH Nanoparticles comprising a stabilized boronic acid compound
WO2017164334A1 (ja) * 2016-03-23 2017-09-28 公益財団法人 川崎市産業振興財団 ホウ素クラスター結合ペプチド化合物
JP7387330B2 (ja) * 2019-08-09 2023-11-28 東和薬品株式会社 ボルテゾミブ保存用容器

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3257029B2 (ja) 1992-04-22 2002-02-18 日本油脂株式会社 フェニルボロン酸誘導体及び製造方法
JPH083172A (ja) 1994-06-15 1996-01-09 Nippon Oil & Fats Co Ltd フェニルボロン酸誘導体および製造方法
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
JP2002179683A (ja) 2000-12-13 2002-06-26 Japan Science & Technology Corp ポリアミノ酸誘導体から成る核酸関連物質反応試薬
SI1695991T1 (sl) * 2003-12-10 2010-04-30 Toudai Tlo Ltd Koordinacijski kompleks diaminocikloheksan platine (II) z blok kopolimerom, ki vsebuje segment poli(karboksilne kisline) in antitumorni agens, ki jih vsebuje
NZ575964A (en) * 2006-10-19 2011-12-22 Nanocarrier Co Ltd Block copolymer for drug complex and pharmaceutical composition
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
US8980241B2 (en) 2008-05-02 2015-03-17 University Of Tsukuba Polymerized cyclic nitroxide radical compound and use thereof
KR101468268B1 (ko) 2008-07-29 2014-12-02 나노캬리아 가부시키가이샤 약물 내포 액티브 타겟형 고분자 미셀, 의약 조성물
EP2323628B1 (en) 2008-08-13 2022-04-13 California Institute of Technology Carrier nanoparticles and related compositions, methods and systems
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
JP5622188B2 (ja) 2010-01-05 2014-11-12 独立行政法人物質・材料研究機構 フェニルボロン酸系単量体及びフェニルボロン酸系重合体
JP2011173960A (ja) 2010-02-23 2011-09-08 Univ Of Tsukuba 高分子ミセル型光刺激応答性一酸化窒素供与体
AU2012233171B2 (en) 2011-03-31 2015-08-20 Nanocarrier Co., Ltd. Pharmaceutical composition containing block copolymer comprising boronic acid compound
CN102391504B (zh) * 2011-09-05 2013-05-15 中国科学院长春应用化学研究所 共聚物、葡萄糖敏感胶束、葡萄糖敏感载药胶束及其制备方法
RU2014124333A (ru) 2011-11-17 2015-12-27 Дзе Юниверсити Оф Токио Блок-сополимер, имеющий введенную в него группу фенилбороновой кислоты, и его применение
JP5603522B2 (ja) * 2012-07-30 2014-10-08 帝人株式会社 非水電解質電池用セパレータおよび非水電解質電池

Also Published As

Publication number Publication date
KR20140038376A (ko) 2014-03-28
EP2692777A4 (en) 2014-11-05
KR101869125B1 (ko) 2018-06-19
JP5086497B1 (ja) 2012-11-28
EP2692777A1 (en) 2014-02-05
MX2013010234A (es) 2014-03-31
TWI533885B (zh) 2016-05-21
CN103502319A (zh) 2014-01-08
MX348798B (es) 2017-06-29
US9561284B2 (en) 2017-02-07
CA2828700A1 (en) 2012-10-04
AU2012233171A1 (en) 2013-09-19
TW201244739A (en) 2012-11-16
RU2013148535A (ru) 2015-05-10
JPWO2012133884A1 (ja) 2014-07-28
CN103502319B (zh) 2015-11-25
EP2692777B1 (en) 2018-10-31
WO2012133884A1 (ja) 2012-10-04
AU2012233171B2 (en) 2015-08-20
RU2569847C2 (ru) 2015-11-27
US20140017192A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
BR112013025005A2 (pt) composição farmacêutica contendo copolímero por blocos compreendendo composto de ácido borônico
BRPI0910388A2 (pt) agentes terapêutico antivirais.
BR112018071093A2 (pt) composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo
BR112015028452A2 (pt) agonistas do receptor somastatina subtipo 4 (sstr4)
BR112013031039A2 (pt) hidrazino 1h-imidazoquinolina-4-aminas e conjugados feitos disso
BR112013020996A2 (pt) derivados aminobutíricos substituídos como inibidores de neprilisina
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015010649A2 (pt) moduladores de gpr40 à base de pirrolidina
MY172924A (en) Neprilysin inhibitors
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112013016595A2 (pt) inibidores de neprilisina
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
EA201270216A1 (ru) Фармацевтический состав
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BR112014022780A8 (pt) composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
BRPI1014802B8 (pt) profármacos de triptolida.
BR112012014721A2 (pt) composição de hormônio do crescimento
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112012031340A2 (pt) derivados de cianoquinolina
CO6321288A2 (es) Sales de compuestos inhibidores de vih

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NANOCARRIER CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2560 DE 2020-01-28